Neuroscience Education for Nurses - Subarachnoid Hemorrhages

Friday, March 1, 2024, 1:00 PM - Monday, March 1, 2027, 2:00 PM

ANCC Nursing Contact Hours (1.25 hours), General Attendance (1.25 hours)

This series is intended to address the gaps of knowledge surrounding neuro specific conditions and interventions provided to patients within the NCCU/NSCU. Through this educational series, staff are going to learn how to perform and utilize various forms of assessment skills to enhance patient care.

1. Discuss the disease process of Subarachnoid Hemorrhages to provide quality care to this patient population.
2. Describe Subarachnoid Hemorrhages including its relation to disease processes.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.25 ANCC contact hours.

All other learners may claim General participation credit. Consult your professional licensing board regarding the applicability and acceptance of general attendance credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.
2. Register for the activity.
3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.
4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).
5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.
6. Complete and Submit the Evaluation.

Bibliographic Sources

• Yee AH, Burns JD, Widjicks EFM, “Cerebral salt wasting: pathophysiology, diagnosis, and treatment.” Neurosurgery Clinics, 21, 339-352, 2010.
  
  
• Allen GS, Ahn HS, Preziosi TJ et al, “Cerebral arterial spasm – a controlled trial of nimodipine in patients with subarachnoid hemorrhage.” New England Journal of Medicine, 308, 619-624, 1983.
  
  
• Rosen DS and Macdonald RL, “Subarachnoid hemorrhage grading scales: a systematic review.” Neurocritical Care, 2, 110-118, 2005.
  
  
• Hoh BL, Topcuoglu MA, Singhal AB et al, “Effect of clipping, craniotomy, or intravascular coiling on cerebral vasospasm and patient outcome after aneurysmal subarachnoid hemorrhage.”  Neurosurgery, 55, 779-789, 2004.
  
  
• Lin N, Brouillard AM, Krishna C et al, “Use of coils in conjunction with the pipeline embolization device for treatment of intracranial aneurysms.”  Neurosurgery, 76, 142-149, 2015.
  
  
• Chalouhi N, Zanaty M, Whiting A, et al, “Treatment of ruptured intracranial aneurysms with the pipeline embolization device.”  Neurosurgery, 76, 165-172, 2015.
  
  
• Hafeez S and Grandhi R, “Systematic review of intratheal nicardipine for the treatment of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.”  Neurocritical Care, 31, 399-405, 2019.
  
  
• Velderman M, Weiss M, Albanna W et al, “Incremental versus immediate induction of hypertension in the treatment of delayed cerebral ischemia after subarachnoid hemorrhage.”  Neurocritical Care, 36, 702-714, 2022.
  
  
• Webster Crowley R, Medel R, Dumont AS et al, “Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage.”  Stroke, 42, 919-923, 2011.
  
  
• Wong GKC, Chan DYC, Siu DYW et al, “High-dose simvastatin for aneurysmal subarachnoid hemorrhage (HDS-SAH Trial),” Stroke, 46, 382-388, 2015.
  
  
• Solar P, Mackerle Z, Joukal M, Jancalek R, “Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review.”  Neurosurgical Review, 1, 2020.
  
  
• Tarabini Fraticelli A, Cholley BP, Losser MR, Saint Maurice JP, “Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.”  Stroke, 39, 893-898, 2008.
  
  
• Francoeur CL and Mayer SA, “Management of delayed cerebral ischemia after subarachnoid hemorrhage.”  Critical Care, 20, 2016.
  
  
• Jun P, Ko NU, English JD et al, “Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage.”  American Journal of Neuroradiology, 31, 1911-1916, 2010.
  
  
• Kimball MM, Velat GJ and Hoh BL, “Critical care guidelines on the endovascular management of cerebral vasospasm.”  Neurocritical Care, 15, 336-341, 2011.
  
  
• Saqqur M, Zygun D and Demchuk A, “Role of transcranial doppler in neurocritical care.” Critical Care Medicine, 35, 2007.
  
  
• Zafar SF, Rosenthal ES, Postma EN et al, “Antiseizure medication treatment and outcomes in patients with subarachnoid hemorrhage undergoing continuous EEG monitoring.”  Neurocritical Care, 36, 857-867, 2022.
  
  
• Wijdicks EFM, “On aneurysmal rupture and rerupture.”  Neurocritical Care, 29, 161-164, 2018.
  
  
• Post R, Germans MR, Tjerkstra MA et al, “Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): a randomized controlled trial.”  Lancet, 397, 112-118, 2021.
  
  
• Mastantuono JM, Combescure C, Elia N et al, “Transcranial doppler in the diagnosis of cerebral vasospasm: an updated meta-analysis.”  Critical Care Medicine, 46, 1665-1672, 2018.
  
  
• Muehlschlegel S, “Subarachnoid hemorrhage.”  Continuum, 2416, 1623-1657, 2018.
  
  
• Maciel CB, Barlow B, Lucke-Wold B et al, “Acute headache management for patients with subarachnoid hemorrhage: an international survey of healthcare providers.” Neurocritical Care, 2022.
  
  
• Censullo J, Wahab AA, Mulkey M et al, “Nursing care of the patient with aneurysmal subarachnoid hemorrhage.”  AANN Clinical Practice Guideline Series, 2018.
  
  
• De Oliveira Manoel AL, Goffi A, Marotta TR et al, “The critical care management of poor-grade subarachnoid hemorrhage.”  Critical Care, 20, 21, 2016.
  
  
• Maagaard M, Karlsson WK, Ovesen C et al, “Interventions for altering blood pressure in people with acute subarachnoid hemorrhage (review).” Cochrane Database of Systematic Reviews, 11, 2021.
  
  
• Lakhal K, Hivert A, Alexandre PL et al, “Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage: the MILRISPASM controlled before-after study.”  Neurocritical Care, 35, 669-679, 2021.
  
  
• Kieninger M, Gruber M, Knott I et al, “Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage.”  Neurocritical Care, 2019.
  
  
• Etminan N, Chang HS, Hackenberg K et al, “Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis.”  JAMA Neurology, 76, 588-597, 2019.
  
  
• Hoh BL, Ko NU, Amin-Hanjani S et al, “2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the AHA/ASA.”  Stroke, 54, e314-e370, 2023.
  
  
• Jabbarli R, Pierscianek D, Rolz R et al, “Endovascular treatment of cerebral vasospasm after subarachnoid hemorrhage.” Neurology, 93, e458-e466, 2019.
  
  
• Weiss M, Albanna W, Conzen C et al, “Optimal cerebral perfusion pressure during delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.”  Critical Care Medicine, 2022.
  
  
• Lawton MT and Vates E, “Subarachnoid Hemorrhage.” New England Journal of Medicine, 377, 257-266, 2017.
  
  
• Stoddard A and Lynch-Smith D, “Neurogenic stunned myocardium: a review.” AACN Advanced Critical Care, 32, 275-282, 2021.
  
  
• Fried HI, Nathan BR, Rowe AS et al, “The insertion and management of external ventricular drains: an evidence-based consensus statement.” Neurocritical Care, 24, 61-81, 2016.
  
  

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
CE Office
Dartmouth Health
[email protected]

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.